The name is a bit of a mouthful, but surprised that there has been no talk of this NZ company that listed on the ASX late December
The Company has a Phase 2B drug, MIS416, to treat secondary progressive multiple sclerosis (SPMS). Currently no approved drugs for the ongoing treatments of this form of MS.
Has received a decent chunk of funding from the NZ Govt for its phase 1B and 2A trials. Currently 23 patients havebeen treated with MIS416 under aCompassionate Use Program and 14 out of the 17 patients with SPMS reported significant improvement insymptoms after 6 months.
Undercapitalised at $33m for a drug at Phase 2B stage- PBT is a decent example of where IIL could go: m/c of $550m
RBS Morgans has a 69c target - link to Research Report below
http://www.innateimmunotherapeutics....nding-tall.pdf
Bookmarks